MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
17.89
+0.32
+1.82%
Pre Market: 17.56 -0.33 -1.84% 06:28 01/22 EST
OPEN
17.86
PREV CLOSE
17.57
HIGH
18.00
LOW
17.62
VOLUME
54
TURNOVER
0
52 WEEK HIGH
29.29
52 WEEK LOW
14.15
MARKET CAP
2.98B
P/E (TTM)
23.07
1D
5D
1M
3M
1Y
5Y
1D
TD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks · 1d ago
Pacira appoints Teehan as CCO, Corbett as CBO
TipRanks · 1d ago
Weekly Report: what happened at ACAD last week (0113-0117)?
Weekly Report · 2d ago
ACADIA PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 5d ago
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)
Barchart · 6d ago
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals
NASDAQ · 01/15 17:42
Bank of America Securities Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)
TipRanks · 01/15 10:17
Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?
The Motley Fool · 01/15 03:21
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.